Dr. Felix Kratz
Tumor Biology Center, Germany

Email: kratz@tumorbio.uni-freiburg.de

Qualifications
1991  Postdoctoral researcher, Bioinorganic Institute, University of Florence
1988  Ph.D., Inorganic Department of Chemistry, University of Heidelberg

Publications (Selected)

1. Kratz, F. S., Möllerherm, L., & Kierfeld, J. (2023). Enhancing robustness, precision, and speed of traction force microscopy with machine learning. Biophysical Journal, 122(17), 3489-3505.
2. Ginot, G., Kratz, F. S., Walzel, F., Farago, J., Kierfeld, J., Höhler, R., & Drenckhan, W. (2021). Pressure–deformation relations of elasto-capillary drops (droploons) on capillaries. Soft Matter, 17(40), 9131-9153.
3. Ryu, J. S., Kratz, F., & Raucher, D. (2021). Cell-penetrating doxorubicin released from elastin-like polypeptide kills doxorubicin-resistant cancer cells in in vitro study. International Journal of Molecular Sciences, 22(3), 1126.
4. Bhattacharjee, T., Amchin, D. B., Ott, J. A., Kratz, F., & Datta, S. S. (2021). Chemotactic migration of bacteria in porous media. Biophysical Journal, 120(16), 3483-3497.
5. Kratz, F. S., & Kierfeld, J. (2020). Pendant drop tensiometry: A machine learning approach. The Journal of Chemical Physics, 153(9).
6. Daum, S., Magnusson, J. P., Pes, L., Garcia Fernandez, J., Chercheja, S., Medda, F., ... & Kratz, F. (2019). Development of a novel imaging agent for determining albumin uptake in solid tumors. Nuclear Medicine and Molecular Imaging, 53, 189-198.
7. Pes, L., Koester, S. D., Magnusson, J. P., Chercheja, S., Medda, F., Ajaj, K. A., ... & Kratz, F. (2019). Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound. Journal of Controlled Release, 296, 81-92.
8. Elsadek, B., Mansour, A., Saleem, T., Warnecke, A., & Kratz, F. (2017). The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. Digestive and Liver Disease, 49(2), 213-222.
9. Eldar-Boock, A., Blau, R., Ryppa, C., Baabur-Cohen, H., Many, A., Vicent, M. J., ... & Satchi-Fainaro, R. (2017). Integrin-targeted nano-sized polymeric systems for paclitaxel conjugation: a comparative study. Journal of drug targeting, 25(9-10), 829-844.
10. M. Calderón, R. Haag, F. Kratz (2011): Säurelabile Nanotransporter als neuartige Drug-Delivery-Systeme zur Behandlung von Krebserkrankungen,Journal Onkologie 3, 152-155.
11. D. Ren, F. Kratz, S. Wang (2011): Protein nanocapsules containing doxorubicin as a pH-responsive delivery system,Small, 7,1051-60.
12. Anticancer macromolecular prodrugs in clinical trials – an update (2010), Hot topic edition with contributions by H. Zhao, R.J. Fram, C.S. Young, D. Nowotnik and F. Kratz,Curr. Bioactive Compounds 7,(ed. F. Kratz).
13. INNO-206 (DOXO-EMCH), an albumin-binding prodrug of doxorubicin for phase II studies against pancreatic, gastric cancer and sarcoma, in Anticancermacromolecular prodrugs in clinical trials – an update (2010), Hot topic edition,Curr. Bioactive Compounds 7(ed. F. Kratz), 33-38.
14. F. Kratz: Drug Delivery in Oncology − Challenges and Perspectives inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy,(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).
15. K. Mross, F. Kratz: Limits of Conventional Chemotherapy inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy,(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled for October 2011).
16. K. Abu Ajaj, F. Kratz: Clinical Experience with Drug Polymer Conjugates, inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy,(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
17. K. Hochdörffer, G. Gi Stefano, H. Maeda, F. Kratz: Liver Tumor Targeting, inDrug Delivery in Oncology – from Research Concepts to Cancer Therapy(eds. F. Kratz, H. Steinhagen, P. Senter), Three-volume edition, 55 chapters, WILEY-VCH scheduled October 2011).
18. G. J. Molderings, M. Raithel, F. Kratz, M. Azemar, B. Haenisch, S. Harzer, J. Homann (2011): Omalizumab treatment of systemic mast cell disease: experiences from four cases.Internal Medicine,50, 611-5.
19. M. Calderón, P Welker, K. Licha, I. Fichtner, R. Graeser, R. Haag, F. Kratz (2011): Development of efficient acid-cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell,J. Controlled Release, 151, 295-301.
20. B. Elsadek, R. Graeser, N. Esser, C. Schäfer-Obodozie, C. Tsurumi, A.Warnecke, C. Unger, T. Saleem, F. Kratz (2011): A novel albumin-binding prodrug of doxorubicinwith improved efficacy against prostate cancer metastases,Prostate Cancer and Prostate Disease, 14,14-21.
21. M. Shama, C. Ryppa, F. Kratz, D. Raucher (2010): Thermally targeted delivery of an acid-sensitive hydrazone derivative of paclitaxel by elastin-like polypeptide,Investigational New Drugs, [Epub ahead of press].
22. B. Elsadek, R. Graeser, N. Esser, C. Schäfer-Obodozie, K. Abu Ajaj, C. Unger, A. Warnecke, T. Saleem, N. El-Melegy, H. Madkor, F. Kratz (2010): Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: anin vitroandin vivoevaluation study,Eur. J. Cancer, 46, 3434-44.
23. I. Müller, F. Kratz, M. Jung, A. Warnceke (2010): Schiff bases derived from p-aminobenzyl alcohol as trigger groups for pH-dependent prodrug activation,Tetrahedron Letters,51, 4371-4374.
24. B. Elsadek, R. Graeser, A. Warnecke, C. Unger, T Saleem,. Nagla El-Melegy, H. Madkor, F. Kratz (2010): Optimization of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA),ACS Med. Chem.Lett. 1, 234-238.
25. D. Polyak, C. Ryppa, A. Eldar-Boock, K. Licha, F. Kratz, P. Ofek, R. Satchi-Fainaro (2010): PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for tumor integrin targeting,Polymers for Advanced Technologies, in press.
26. F. Kratz (2010): Albumin, a versatile drug carrier in oncology,Int. J. Clin. Pharm. Ther.48, 453-455.
27. R. Graeser, N. Esser, H. Unger, I. Fichtner, A. Zhu, C. Unger, F. Kratz (2010): INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model,Investigational New Drugs,28, 14-19.
28. M. Calderón, P. Welker, K. Licha, R. Graeser R, F. Kratz, R. Haag (2010): Development of efficient macromolecular prodrugs derived from dendritic polyglycerol,J. Controlled Release 20;148(1):e24-5.

Profile Details

https://scholar.google/citations?user=FwBUP5QAAAAJ&hl=en